1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Orbimed Advisors Llc Buys Guardant Health Inc, CVS Health Corp, Celgene Corp, Sells Jazz Pharmaceuticals PLC, Alexion Pharmaceuticals Inc, Bristol-Myers Squibb Company

New York, NY, based Investment company Orbimed Advisors Llc buys Guardant Health Inc, CVS Health Corp, Celgene Corp, Intuitive Surgical Inc, Bausch Health Inc, Centene Corp, Neurocrine Biosciences Inc, DexCom Inc, MyoKardia Inc, Deciphera Pharmaceuticals Inc, Tenet Healthcare Corp, Clovis Oncology Inc, Tandem Diabetes Care Inc, Intercept Pharmaceuticals Inc, Gilead Sciences Inc, Adaptimmune Therapeutics PLC, Apellis Pharmaceuticals Inc, Sage Therapeutics Inc, MeiraGTx Holdings PLC, The Medicines Co, Amarin Corp PLC, sells Jazz Pharmaceuticals PLC, Alexion Pharmaceuticals Inc, Bristol-Myers Squibb Company, Edwards Lifesciences Corp, Vertex Pharmaceuticals Inc, Boston Scientific Corp, Nevro Corp, Merck Inc, Array BioPharma Inc, Dentsply Sirona Inc, Regeneron Pharmaceuticals Inc, Mednax Inc, DaVita Inc, Humana Inc, Johnson & Johnson, Loxo Oncology Inc, Thermo Fisher Scientific Inc, Anthem Inc, Wright Medical Group NV, Galapagos NV, Teleflex Inc, Insmed Inc, Cigna Corp, Insys Therapeutics Inc, Coherus BioSciences Inc, Molina Healthcare Inc, Inspire Medical Systems Inc, Agilent Technologies Inc, CRISPR Therapeutics AG, Aerie Pharmaceuticals Inc, Aetna Inc, Rocket Pharmaceuticals Inc, Select Medical Holdings Corp, Amicus Therapeutics Inc, DBV Technologies SA, eHealth Inc, Immunogen Inc, Pieris Pharmaceuticals Inc, Radius Health Inc, Global Blood Therapeutics Inc, ProQR Therapeutics NV, Intellia Therapeutics Inc, McKesson Corp, Fluidigm Corp, Invitae Corp, Alkermes PLC, Menlo Therapeutics Inc, Neuronetics Inc, Catalyst Pharmaceuticals Inc, GW Pharmaceuticals PLC, Tesaro Inc, Syndax Pharmaceuticals Inc, Adamas Pharmaceuticals Inc, Redhill Biopharma, Sierra Oncology Inc during the 3-months ended 2018Q4, according to the most recent filings of the investment company, Orbimed Advisors Llc. As of 2018Q4, Orbimed Advisors Llc owns 124 stocks with a total value of $5.2 billion. These are the details of the buys and sells.

For the details of ORBIMED ADVISORS LLC's stock buys and sells, go to https://www.gurufocus.com/guru/orbimed+advisors+llc/current-portfolio/portfolio

These are the top 5 holdings of ORBIMED ADVISORS LLC
  1. Tricida Inc (TCDA) - 10,889,280 shares, 4.93% of the total portfolio.
  2. Ascendis Pharma A/S (ASND) - 4,087,373 shares, 4.91% of the total portfolio. Shares reduced by 1.65%
  3. Biogen Inc (BIIB) - 835,249 shares, 4.82% of the total portfolio. Shares reduced by 8.24%
  4. Celgene Corp (CELG) - 3,256,700 shares, 4.01% of the total portfolio. Shares added by 32.18%
  5. Boston Scientific Corp (BSX) - 5,790,400 shares, 3.93% of the total portfolio. Shares reduced by 26.37%
New Purchase: Guardant Health Inc (GH)

Orbimed Advisors Llc initiated holding in Guardant Health Inc. The purchase prices were between $29.2 and $46.1, with an estimated average price of $36.87. The stock is now traded at around $66.82. The impact to a portfolio due to this purchase was 1.11%. The holding were 1,534,464 shares as of .

New Purchase: CVS Health Corp (CVS)

Orbimed Advisors Llc initiated holding in CVS Health Corp. The purchase prices were between $62.92 and $80.8, with an estimated average price of $74.46. The stock is now traded at around $53.75. The impact to a portfolio due to this purchase was 1%. The holding were 793,800 shares as of .

New Purchase: DexCom Inc (DXCM)

Orbimed Advisors Llc initiated holding in DexCom Inc. The purchase prices were between $107.97 and $149.46, with an estimated average price of $126.42. The stock is now traded at around $144.09. The impact to a portfolio due to this purchase was 0.32%. The holding were 138,700 shares as of .

New Purchase: MyoKardia Inc (MYOK)

Orbimed Advisors Llc initiated holding in MyoKardia Inc. The purchase prices were between $46.92 and $62.07, with an estimated average price of $54.99. The stock is now traded at around $52.38. The impact to a portfolio due to this purchase was 0.31%. The holding were 335,100 shares as of .

New Purchase: Tenet Healthcare Corp (THC)

Orbimed Advisors Llc initiated holding in Tenet Healthcare Corp. The purchase prices were between $16.85 and $29.29, with an estimated average price of $24.01. The stock is now traded at around $27.96. The impact to a portfolio due to this purchase was 0.19%. The holding were 562,785 shares as of .

New Purchase: Intercept Pharmaceuticals Inc (ICPT)

Orbimed Advisors Llc initiated holding in Intercept Pharmaceuticals Inc. The purchase prices were between $85.79 and $119.4, with an estimated average price of $103.17. The stock is now traded at around $104.85. The impact to a portfolio due to this purchase was 0.09%. The holding were 47,800 shares as of .

Added: Celgene Corp (CELG)

Orbimed Advisors Llc added to a holding in Celgene Corp by 32.18%. The purchase prices were between $59.21 and $91.87, with an estimated average price of $73.23. The stock is now traded at around $85.26. The impact to a portfolio due to this purchase was 0.98%. The holding were 3,256,700 shares as of .

Added: Intuitive Surgical Inc (ISRG)

Orbimed Advisors Llc added to a holding in Intuitive Surgical Inc by 84.92%. The purchase prices were between $434.89 and $571.48, with an estimated average price of $506.12. The stock is now traded at around $542.95. The impact to a portfolio due to this purchase was 0.72%. The holding were 170,500 shares as of .

Added: Bausch Health Companies Inc (BHC)

Orbimed Advisors Llc added to a holding in Bausch Health Companies Inc by 89.10%. The purchase prices were between $17.64 and $28.32, with an estimated average price of $23.64. The stock is now traded at around $23.47. The impact to a portfolio due to this purchase was 0.6%. The holding were 3,600,300 shares as of .

Added: Centene Corp (CNC)

Orbimed Advisors Llc added to a holding in Centene Corp by 147.42%. The purchase prices were between $54.55 and $73.42, with an estimated average price of $66.73. The stock is now traded at around $57.45. The impact to a portfolio due to this purchase was 0.55%. The holding were 834,800 shares as of .

Added: Neurocrine Biosciences Inc (NBIX)

Orbimed Advisors Llc added to a holding in Neurocrine Biosciences Inc by 258.64%. The purchase prices were between $68.32 and $119.1, with an estimated average price of $94.71. The stock is now traded at around $80.03. The impact to a portfolio due to this purchase was 0.49%. The holding were 494,200 shares as of .

Added: Deciphera Pharmaceuticals Inc (DCPH)

Orbimed Advisors Llc added to a holding in Deciphera Pharmaceuticals Inc by 25.02%. The purchase prices were between $19.08 and $36.14, with an estimated average price of $24.36. The stock is now traded at around $26.79. The impact to a portfolio due to this purchase was 0.2%. The holding were 2,442,200 shares as of .

Sold Out: Jazz Pharmaceuticals PLC (JAZZ)

Orbimed Advisors Llc sold out a holding in Jazz Pharmaceuticals PLC. The sale prices were between $115.94 and $166.74, with an estimated average price of $147.58.

Sold Out: Nevro Corp (NVRO)

Orbimed Advisors Llc sold out a holding in Nevro Corp. The sale prices were between $35.43 and $55.36, with an estimated average price of $44.01.

Sold Out: Array BioPharma Inc (ARRY)

Orbimed Advisors Llc sold out a holding in Array BioPharma Inc. The sale prices were between $12.92 and $17.36, with an estimated average price of $15.15.

Sold Out: Dentsply Sirona Inc (XRAY)

Orbimed Advisors Llc sold out a holding in Dentsply Sirona Inc. The sale prices were between $34.32 and $38.12, with an estimated average price of $36.37.

Sold Out: Mednax Inc (MD)

Orbimed Advisors Llc sold out a holding in Mednax Inc. The sale prices were between $32.26 and $46.43, with an estimated average price of $40.08.

Sold Out: Johnson & Johnson (JNJ)

Orbimed Advisors Llc sold out a holding in Johnson & Johnson. The sale prices were between $122.84 and $147.84, with an estimated average price of $139.37.

Reduced: Alexion Pharmaceuticals Inc (ALXN)

Orbimed Advisors Llc reduced to a holding in Alexion Pharmaceuticals Inc by 28.94%. The sale prices were between $93.94 and $136.71, with an estimated average price of $117.6. The stock is now traded at around $132.04. The impact to a portfolio due to this sale was -1.41%. Orbimed Advisors Llc still held 2,047,400 shares as of .

Reduced: Bristol-Myers Squibb Company (BMY)

Orbimed Advisors Llc reduced to a holding in Bristol-Myers Squibb Company by 75.03%. The sale prices were between $48.76 and $63.23, with an estimated average price of $53.49. The stock is now traded at around $50.90. The impact to a portfolio due to this sale was -1.15%. Orbimed Advisors Llc still held 505,900 shares as of .

Reduced: Edwards Lifesciences Corp (EW)

Orbimed Advisors Llc reduced to a holding in Edwards Lifesciences Corp by 53%. The sale prices were between $139.22 and $163.94, with an estimated average price of $151.35. The stock is now traded at around $173.56. The impact to a portfolio due to this sale was -1.11%. Orbimed Advisors Llc still held 465,600 shares as of .

Reduced: Vertex Pharmaceuticals Inc (VRTX)

Orbimed Advisors Llc reduced to a holding in Vertex Pharmaceuticals Inc by 29.2%. The sale prices were between $151.91 and $192.21, with an estimated average price of $172.53. The stock is now traded at around $180.51. The impact to a portfolio due to this sale was -1.09%. Orbimed Advisors Llc still held 1,133,200 shares as of .

Reduced: Boston Scientific Corp (BSX)

Orbimed Advisors Llc reduced to a holding in Boston Scientific Corp by 26.37%. The sale prices were between $31.73 and $39.04, with an estimated average price of $36.14. The stock is now traded at around $39.90. The impact to a portfolio due to this sale was -0.97%. Orbimed Advisors Llc still held 5,790,400 shares as of .

Reduced: Merck & Co Inc (MRK)

Orbimed Advisors Llc reduced to a holding in Merck & Co Inc by 29.61%. The sale prices were between $68.37 and $79.34, with an estimated average price of $74.05. The stock is now traded at around $80.87. The impact to a portfolio due to this sale was -0.9%. Orbimed Advisors Llc still held 2,495,000 shares as of .



Here is the complete portfolio of ORBIMED ADVISORS LLC. Also check out:

1. ORBIMED ADVISORS LLC's Undervalued Stocks
2. ORBIMED ADVISORS LLC's Top Growth Companies, and
3. ORBIMED ADVISORS LLC's High Yield stocks
4. Stocks that ORBIMED ADVISORS LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK